About MAP Pharmaceuticals
MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. The company is developing LEVADEX™ inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of the first Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.
|
|
|
51-200 employees
View all MAP Pharmaceuticals employees
|
|
Pharmaceutical Manufacturing
|
|
US
|
|
2005
|
|
Inhalation Technology And Neurology And Device Delivery Systems
|
MAP Pharmaceuticals Alternatives
Frequently Asked Questions about MAP Pharmaceuticals
Ashish Kesari is the CEO of MAP Pharmaceuticals. To contact Ashish Kesari email at [email protected] or [email protected].
The decision makers in MAP Pharmaceuticals are Ashish Kesari, Ashish Kesari, Larrain Taberna, etc. Click to Find MAP Pharmaceuticals decision makers emails.
MAP Pharmaceuticals Staff Directory
Search MAP Pharmaceuticals Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.
